Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 7
2011 3
2012 5
2013 9
2014 10
2015 5
2016 4
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, Berrey M, Symonds B, De La Rosa A, Cammack N, Nájera I. Le Pogam S, et al. J Infect Dis. 2010 Nov 15;202(10):1510-9. doi: 10.1086/656774. Epub 2010 Oct 13. J Infect Dis. 2010. PMID: 20942646 Clinical Trial.
RESULTS: From 32 patients treated with RG7128 monotherapy for 2 weeks, marginal viral load rebound was observed in 3 HCV genotype 1-infected patients, whereas partial response was observed in 2 genotype 1-infected patients. From 85 patients receiving RG7128 in combi …
RESULTS: From 32 patients treated with RG7128 monotherapy for 2 weeks, marginal viral load rebound was observed in 3 HCV genotype 1-i …
Anti-HCV drugs in the pipeline.
Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Yang PL, et al. Curr Opin Virol. 2011 Dec;1(6):607-16. doi: 10.1016/j.coviro.2011.10.019. Epub 2011 Nov 13. Curr Opin Virol. 2011. PMID: 22440918 Free PMC article. Review.
Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor …
Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the mos …
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
We assessed the safety, tolerability, and antiviral activity of an all-oral combination treatment with two experimental anti-HCV drugs-RG7128, a nucleoside polymerase inhibitor; and danoprevir, an NS3/4A protease inhibitor-in patients with chronic HCV infection. ...The com …
We assessed the safety, tolerability, and antiviral activity of an all-oral combination treatment with two experimental anti-HCV drugs-RG …
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Guedj J, Dahari H, Shudo E, Smith P, Perelson AS. Guedj J, et al. Hepatology. 2012 Apr;55(4):1030-7. doi: 10.1002/hep.24788. Epub 2012 Feb 15. Hepatology. 2012. PMID: 22095398 Free PMC article. Clinical Trial.
Mericitabine (RG7128) is a nucleoside polymerase inhibitor (NPI), which requires intracellular uptake and phosphorylation to two active triphosphates. ...
Mericitabine (RG7128) is a nucleoside polymerase inhibitor (NPI), which requires intracellular uptake and phosphorylation to two acti …
Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.
Chow J, Liu Y, Comstock K, Brandl M, Lin F, Li F, Sarma K, Alfredson T. Chow J, et al. J Pharm Biomed Anal. 2010 Nov 2;53(3):710-6. doi: 10.1016/j.jpba.2010.04.003. Epub 2010 Apr 9. J Pharm Biomed Anal. 2010. PMID: 20439144
RG7128 is a di-ester prodrug of a cytidine analog for the treatment of hepatitis C virus (HCV) infection. ...Heart-cut and recycle chromatographic techniques were applied to purify closely eluting isomers of RG7128....
RG7128 is a di-ester prodrug of a cytidine analog for the treatment of hepatitis C virus (HCV) infection. ...Heart-cut and recycle ch …
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Pawlotsky JM, Najera I, Jacobson I. Pawlotsky JM, et al. Antivir Ther. 2012;17(3):411-23. doi: 10.3851/IMP2088. Epub 2012 Mar 8. Antivir Ther. 2012. PMID: 22402762 Review.
Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV. ...
Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of t …
Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides.
Chang W, Du J, Rachakonda S, Ross BS, Convers-Reignier S, Yau WT, Pons JF, Murakami E, Bao H, Steuer HM, Furman PA, Otto MJ, Sofia MJ. Chang W, et al. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4539-43. doi: 10.1016/j.bmcl.2010.06.025. Epub 2010 Jun 8. Bioorg Med Chem Lett. 2010. PMID: 20580554
Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to treat this disease. Our first generation nucleoside HCV inhibitor, RG7128 has already established proof-of-concept in the clinic and …
Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to …
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, Germer S, Iglesias VA, Elston R, Smith PF, Shulman NS. Chu TW, et al. Gastroenterology. 2012 Apr;142(4):790-5. doi: 10.1053/j.gastro.2011.12.057. Epub 2012 Jan 13. Gastroenterology. 2012. PMID: 22248659 Clinical Trial.
We analyzed the effects of IL28B genotype on the viral kinetic (VK) response to an interferon-free combination of the nucleoside polymerase inhibitor mericitabine (RG7128) and the hepatitis C virus (HCV) protease inhibitor danoprevir. ...
We analyzed the effects of IL28B genotype on the viral kinetic (VK) response to an interferon-free combination of the nucleoside polymerase …
35 results